183 related articles for article (PubMed ID: 28194053)
1. Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.
Prinja S; Kaur G; Malhotra P; Jyani G; Ramachandran R; Bahuguna P; Varma S
Indian J Hematol Blood Transfus; 2017 Mar; 33(1):31-40. PubMed ID: 28194053
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India.
Dixit J; Malhotra P; Mehra N; Mathew A; Kumar L; Singh A; Gupta N; Krishnamurthy MN; Roy PS; Kataki AC; Gupta S; Prinja S
Appl Health Econ Health Policy; 2024 Mar; ():. PubMed ID: 38448720
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India.
Bahuguna P; Prinja S; Lahariya C; Dhiman RK; Kumar MP; Sharma V; Aggarwal AK; Bhaskar R; De Graeve H; Bekedam H
Appl Health Econ Health Policy; 2020 Jun; 18(3):393-411. PubMed ID: 31741306
[TBL] [Abstract][Full Text] [Related]
4. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis.
Verburg RJ; Sont JK; Vliet Vlieland TP; Landewé RB; Boers M; Kievit J; van Laar JM
J Rheumatol; 2001 Apr; 28(4):719-27. PubMed ID: 11327241
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia.
Qerimi V; Nestorovska AK; Sterjev Z; Genadieva-Stavric S; Suturkova L
Clinicoecon Outcomes Res; 2018; 10():327-338. PubMed ID: 29950875
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
8. Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India.
Kaur G; Prinja S; Malhotra P; Lad DP; Prakash G; Khadwal A; Ramachandran R; Varma S
Indian J Hematol Blood Transfus; 2018 Jan; 34(1):25-31. PubMed ID: 29398796
[TBL] [Abstract][Full Text] [Related]
9. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Temozolamide for Treatment of Glioblastoma Multiforme in India.
Gupta N; Prinja S; Patil V; Bahuguna P
JCO Glob Oncol; 2021 Jan; 7():108-117. PubMed ID: 33449801
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
15. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.
Corso A; Mangiacavalli S; Cocito F; Pascutto C; Ferretti VV; Pompa A; Ciampichini R; Pochintesta L; Mantovani LG
PLoS One; 2013; 8(9):e75047. PubMed ID: 24098678
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
20. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.
Li S; Li J; Peng L; Tan C; Zeng X; Peng C; Zhang C; Li Y; Wan X
Clin Ther; 2021 Jul; 43(7):1253-1264.e5. PubMed ID: 34193346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
